JP2020073504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020073504A5 JP2020073504A5 JP2019229640A JP2019229640A JP2020073504A5 JP 2020073504 A5 JP2020073504 A5 JP 2020073504A5 JP 2019229640 A JP2019229640 A JP 2019229640A JP 2019229640 A JP2019229640 A JP 2019229640A JP 2020073504 A5 JP2020073504 A5 JP 2020073504A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- antibody
- seq
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022019186A JP7492981B2 (ja) | 2013-08-01 | 2022-02-10 | 抗ｇａｒｐタンパク質及びその使用 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361861008P | 2013-08-01 | 2013-08-01 | |
| EP13178958.8A EP2832747A1 (en) | 2013-08-01 | 2013-08-01 | Anti-GARP protein and uses thereof |
| US61/861,008 | 2013-08-01 | ||
| EP13178958.8 | 2013-08-01 | ||
| EP14167425.9 | 2014-05-07 | ||
| EP14167425 | 2014-05-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016530550A Division JP2016529892A (ja) | 2013-08-01 | 2014-08-01 | 抗ｇａｒｐタンパク質及びその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022019186A Division JP7492981B2 (ja) | 2013-08-01 | 2022-02-10 | 抗ｇａｒｐタンパク質及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020073504A JP2020073504A (ja) | 2020-05-14 |
| JP2020073504A5 true JP2020073504A5 (OSRAM) | 2020-10-01 |
Family
ID=52431038
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016530550A Withdrawn JP2016529892A (ja) | 2013-08-01 | 2014-08-01 | 抗ｇａｒｐタンパク質及びその使用 |
| JP2019229640A Pending JP2020073504A (ja) | 2013-08-01 | 2019-12-19 | 抗ｇａｒｐタンパク質及びその使用 |
| JP2022019186A Active JP7492981B2 (ja) | 2013-08-01 | 2022-02-10 | 抗ｇａｒｐタンパク質及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016530550A Withdrawn JP2016529892A (ja) | 2013-08-01 | 2014-08-01 | 抗ｇａｒｐタンパク質及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022019186A Active JP7492981B2 (ja) | 2013-08-01 | 2022-02-10 | 抗ｇａｒｐタンパク質及びその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10000572B2 (OSRAM) |
| EP (2) | EP3027650B1 (OSRAM) |
| JP (3) | JP2016529892A (OSRAM) |
| KR (2) | KR20220025174A (OSRAM) |
| CN (2) | CN113583128A (OSRAM) |
| AU (3) | AU2014298373B2 (OSRAM) |
| BR (1) | BR112016002199B8 (OSRAM) |
| CA (1) | CA2919765C (OSRAM) |
| EA (1) | EA035550B1 (OSRAM) |
| ES (1) | ES2860952T3 (OSRAM) |
| IL (2) | IL243899B (OSRAM) |
| MX (2) | MX377091B (OSRAM) |
| NZ (1) | NZ717476A (OSRAM) |
| SG (2) | SG11201600741SA (OSRAM) |
| WO (1) | WO2015015003A1 (OSRAM) |
| ZA (1) | ZA201601085B (OSRAM) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE052232T2 (hu) | 2013-05-06 | 2021-04-28 | Scholar Rock Inc | Készítmények és eljárások növekedési faktor modulálására |
| KR20220025174A (ko) * | 2013-08-01 | 2022-03-03 | 위니베르시트카솔리끄드루뱅 | 항garp 단백질 항체와 그 용도 |
| WO2016125017A1 (en) * | 2015-02-03 | 2016-08-11 | Universite Catholique De Louvain | Anti-garp protein and uses thereof |
| MX383614B (es) | 2015-05-21 | 2025-03-14 | Harpoon Therapeutics Inc | Proteinas de union triespecificas y metodos de uso. |
| WO2017013276A1 (es) * | 2015-07-22 | 2017-01-26 | Hospital Sant Joan De Deu | Inmunoterapia para el cáncer con expresión de casr (p. ej. neuroblastoma) |
| EP4349997A3 (en) * | 2015-09-24 | 2024-07-10 | Daiichi Sankyo Company, Limited | Anti-garp antibody |
| MX2018006613A (es) * | 2015-12-02 | 2019-01-30 | Stcube & Co Inc | Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos. |
| PL3365368T3 (pl) * | 2016-03-11 | 2023-08-21 | Scholar Rock, Inc. | Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie |
| US11046782B2 (en) | 2016-03-30 | 2021-06-29 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination |
| US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| MX419976B (es) * | 2016-07-14 | 2025-01-14 | Scholar Rock Inc | Anticuerpos de tgfb, métodos, y usos |
| EP3568466A4 (en) | 2017-01-10 | 2020-07-15 | The General Hospital Corporation | TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS |
| CA3059444A1 (en) * | 2017-04-14 | 2018-10-18 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| GB201707561D0 (en) | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| SI3694529T1 (sl) | 2017-10-13 | 2024-10-30 | Harpoon Therapeutics, Inc. | Trispecifične beljakovine in načini uporabe |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| MX2020006213A (es) | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
| WO2019157533A1 (en) * | 2018-02-12 | 2019-08-15 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| EP3833385A4 (en) | 2018-08-08 | 2021-12-22 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| AU2019363368A1 (en) * | 2018-10-16 | 2021-05-13 | Neuracle Science Co., Ltd. | Use of anti-FAM19A5 antibodies |
| EP3902823A1 (en) | 2018-12-24 | 2021-11-03 | Sanofi | Multispecific binding proteins with mutant fab domains |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| JPWO2021079958A1 (OSRAM) * | 2019-10-25 | 2021-04-29 | ||
| AU2020384883B2 (en) | 2019-11-15 | 2023-11-16 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
| AU2021205440A1 (en) | 2020-01-11 | 2022-09-01 | Scholar Rock,Inc. | TGF-beta inhibitors and use thereof |
| JP7511377B2 (ja) * | 2020-04-16 | 2024-07-05 | デンカ株式会社 | アデノウイルスの免疫測定方法及び免疫測定器具 |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| JP7591066B2 (ja) | 2020-06-03 | 2024-11-27 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
| WO2022116877A1 (en) | 2020-12-02 | 2022-06-09 | Shanghai Henlius Biotech, Inc. | ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| JP2024502670A (ja) * | 2021-01-18 | 2024-01-22 | シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド | Ｇａｒｐタンパク質抗体及びその適用 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2022240879A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| EP4416184A4 (en) * | 2021-10-11 | 2025-11-19 | Ohio State Innovation Foundation | Glycoprotein Predominantly Repeating Antibodies (GARP) and Their Uses |
| JP7709612B2 (ja) | 2021-12-08 | 2025-07-16 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| AU2022419982B2 (en) | 2021-12-22 | 2026-04-16 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| GB202203269D0 (en) | 2022-03-09 | 2022-04-20 | Argenx Iip Bv | TGF-Beta antibodies |
| EP4493554A1 (en) | 2022-03-17 | 2025-01-22 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4558823A1 (en) | 2022-07-22 | 2025-05-28 | Institut National de la Santé et de la Recherche Médicale | Garp as a biomarker and biotarget in t-cell malignancies |
| WO2024023797A1 (en) | 2022-07-29 | 2024-02-01 | Abbvie Biotherapeutics Inc. | ANTI-GARP-TGF-β1/PD-1 COMBINATION THERAPY |
| EP4634224A1 (en) | 2022-12-14 | 2025-10-22 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| KR20260022341A (ko) * | 2023-06-05 | 2026-02-19 | 퓨어 바이올로직스 스푸우카 아크치이나 | 항 garp 항체 및 이의 사용 방법 |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AR134560A1 (es) | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026089992A1 (en) | 2024-10-21 | 2026-04-30 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| NZ298145A (en) * | 1994-12-29 | 1998-08-26 | Yamanouchi Pharma Co Ltd | Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament |
| CN1333274A (zh) * | 2000-07-07 | 2002-01-30 | 上海博德基因开发有限公司 | 一种新的多肽——人garp蛋白12.98和编码这种多肽的多核苷酸 |
| US7709610B2 (en) * | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| WO2006103639A2 (en) | 2005-03-31 | 2006-10-05 | Case Western Reserve University | Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals |
| EP2001509A1 (en) | 2006-04-03 | 2008-12-17 | Medizinische Hochschule Hannover | Pharmaceuticals for influencing the reaction of the human immune system |
| CN101808664A (zh) * | 2007-08-24 | 2010-08-18 | 学校法人庆应义墪 | 肿瘤细胞所导致的免疫抑制的解除剂及使用该解除剂的抗肿瘤剂 |
| WO2009055054A2 (en) * | 2007-10-25 | 2009-04-30 | Janda Kim D | Antibody-mediated disruption of quorum sensing in bacteria |
| WO2009073163A1 (en) * | 2007-12-03 | 2009-06-11 | American Type Culture Collection (Atcc) | Avian influenza antibodies, compositions, and methods thereof |
| US20100303828A1 (en) * | 2008-01-31 | 2010-12-02 | INSERM Institut National de la Sante et de la Recherche Medicale) | Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| US8951793B2 (en) | 2008-08-21 | 2015-02-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of making an isolated population of FOXP3+ regulatory T cells |
| EP2977386A1 (en) | 2012-08-31 | 2016-01-27 | Argen-X Nv | Method for producing antibody molecules having inter-species, intra-target cross-reactivity |
| HUE052232T2 (hu) * | 2013-05-06 | 2021-04-28 | Scholar Rock Inc | Készítmények és eljárások növekedési faktor modulálására |
| EP2832747A1 (en) | 2013-08-01 | 2015-02-04 | Université Catholique de Louvain | Anti-GARP protein and uses thereof |
| KR20220025174A (ko) | 2013-08-01 | 2022-03-03 | 위니베르시트카솔리끄드루뱅 | 항garp 단백질 항체와 그 용도 |
| WO2016125017A1 (en) | 2015-02-03 | 2016-08-11 | Universite Catholique De Louvain | Anti-garp protein and uses thereof |
| EP4349997A3 (en) | 2015-09-24 | 2024-07-10 | Daiichi Sankyo Company, Limited | Anti-garp antibody |
| MX419976B (es) | 2016-07-14 | 2025-01-14 | Scholar Rock Inc | Anticuerpos de tgfb, métodos, y usos |
-
2014
- 2014-08-01 KR KR1020227004383A patent/KR20220025174A/ko not_active Ceased
- 2014-08-01 EP EP14748185.7A patent/EP3027650B1/en active Active
- 2014-08-01 WO PCT/EP2014/066650 patent/WO2015015003A1/en not_active Ceased
- 2014-08-01 CN CN202110765205.9A patent/CN113583128A/zh active Pending
- 2014-08-01 US US14/908,368 patent/US10000572B2/en active Active
- 2014-08-01 ES ES14748185T patent/ES2860952T3/es active Active
- 2014-08-01 EA EA201690314A patent/EA035550B1/ru not_active IP Right Cessation
- 2014-08-01 NZ NZ717476A patent/NZ717476A/en unknown
- 2014-08-01 SG SG11201600741SA patent/SG11201600741SA/en unknown
- 2014-08-01 CA CA2919765A patent/CA2919765C/en active Active
- 2014-08-01 BR BR112016002199A patent/BR112016002199B8/pt active IP Right Grant
- 2014-08-01 EP EP20201515.2A patent/EP3786187A1/en not_active Withdrawn
- 2014-08-01 SG SG10201800889SA patent/SG10201800889SA/en unknown
- 2014-08-01 CN CN201480043607.6A patent/CN105658666B/zh active Active
- 2014-08-01 AU AU2014298373A patent/AU2014298373B2/en active Active
- 2014-08-01 JP JP2016530550A patent/JP2016529892A/ja not_active Withdrawn
- 2014-08-01 MX MX2016001356A patent/MX377091B/es active IP Right Grant
- 2014-08-01 KR KR1020167005677A patent/KR102362609B1/ko active Active
-
2016
- 2016-01-29 MX MX2019011952A patent/MX2019011952A/es unknown
- 2016-02-01 IL IL243899A patent/IL243899B/en active IP Right Grant
- 2016-02-02 US US15/013,706 patent/US20160251438A1/en not_active Abandoned
- 2016-02-17 ZA ZA2016/01085A patent/ZA201601085B/en unknown
-
2018
- 2018-05-09 US US15/975,493 patent/US10604579B2/en active Active
-
2019
- 2019-03-29 US US16/370,822 patent/US10822424B2/en active Active
- 2019-11-18 AU AU2019268046A patent/AU2019268046A1/en not_active Abandoned
- 2019-12-19 JP JP2019229640A patent/JP2020073504A/ja active Pending
-
2020
- 2020-02-14 US US16/791,937 patent/US11230603B2/en active Active
- 2020-07-16 IL IL276106A patent/IL276106A/en unknown
-
2021
- 2021-12-03 AU AU2021277761A patent/AU2021277761A1/en not_active Abandoned
-
2022
- 2022-02-10 JP JP2022019186A patent/JP7492981B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7607498B2 (ja) | 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 | |
| CN115052895B (zh) | 抗SIRPα抗体及其用途 | |
| AU2017203523B2 (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15) | |
| JP6728053B2 (ja) | 抗ｍｃａｍ抗体及び関連する使用方法 | |
| JP2022512132A5 (OSRAM) | ||
| JP2019116474A5 (OSRAM) | ||
| JP2019513018A5 (OSRAM) | ||
| JP2022104966A (ja) | ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途 | |
| JP2013502913A5 (OSRAM) | ||
| EP3092252B1 (en) | Antibody targeting cell surface deposited complement protein c3d and use thereof | |
| JP2021512604A5 (OSRAM) | ||
| JP2022513050A5 (OSRAM) | ||
| JP2021511387A5 (OSRAM) | ||
| JP2021529524A5 (OSRAM) | ||
| CN114829405B (zh) | 抗bcma/抗4-1bb双特异性抗体及其用途 | |
| JP2021523906A5 (OSRAM) | ||
| JP2026031937A (ja) | 抗グリカン抗体及びそれらの使用 | |
| KR20250029205A (ko) | 종양 항원에 대한 인간화 항체 또는 이의 기능적 단편 | |
| CA3148562A1 (en) | Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof | |
| JP2023103439A (ja) | 固形腫瘍の治療に有益な抗体およびその抗体－薬物コンジュゲート並びにこれらを含む抗がん剤 | |
| GB2524553A (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer cachexia | |
| KR20250012612A (ko) | 고형 종양을 치료하는 방법 | |
| CN119095878A (zh) | 特异性结合muc-1的抗体及其用途 | |
| RU2822496C1 (ru) | АНТИТЕЛО К SIRPα И ЕГО ПРИМЕНЕНИЕ | |
| CN118159559A (zh) | 一种抗b7-h4抗体及其制备方法和应用 |